|1.||Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
|1.||Dalakas, Marinos C: 18 articles (10/2015 - 12/2002)|
|2.||Hughes, R A C: 18 articles (01/2014 - 04/2002)|
|3.||Hughes, Richard A C: 17 articles (01/2015 - 01/2003)|
|4.||Hartung, Hans-Peter: 16 articles (10/2015 - 04/2002)|
|5.||Nobile-Orazio, Eduardo: 15 articles (10/2015 - 11/2003)|
|6.||Latov, Norman: 14 articles (10/2015 - 06/2003)|
|7.||Brannagan, Thomas H: 14 articles (02/2013 - 12/2002)|
|8.||van Doorn, Pieter A: 13 articles (12/2015 - 06/2005)|
|9.||Bril, Vera: 13 articles (10/2015 - 02/2008)|
|10.||Merkies, Ingemar S J: 10 articles (10/2015 - 02/2008)|
|1.||Intravenous Immunoglobulins (IVIG)FDA Link
08/01/1996 - "Of the 30 patients, 19 (63%) improved with IvIg treatments; nine out of 16 patients (56%) with chronic progressive CIDP, and 10 out of 14 patients (71%) with relapsing CIDP (differences were not statistically significant). "
06/01/1991 - "High-dose IVIG was a safe and effective adjunctive therapy for childhood CIDP in these four patients."
07/01/2015 - "This difference may help to balance the more frequent response to IVIg than to IVMP in patients with CIDP."
05/01/2013 - "SCIG treatment in CIDP is feasible, safe and effective, and seems an attractive alternative to IVIG."
07/01/2008 - "On the basis of available data, IVIg can be recommended as a first-line treatment option for GBS and CIDP. "
11/01/2010 - "Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance."
11/01/2014 - "A sustained clinical efficacy was observed after the switch to subcutaneous immunoglobulin: the Overall Neuropathy Limitation Scale score improved in the group of 66 CIDP patients (P = 0.018), with only one subject reporting a worsening of 1 point, and remained stable in the group of 21 MMN patients (P = 0.841), with one subject reporting a worsening of two points. "
04/14/2009 - "Chronic inflammatory demyelinating polyradiculoneuropathy trials have demonstrated the efficacy of IV immunoglobulin vs placebo. "
01/01/2015 - "Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction."
03/01/2006 - "[Intermittent intravenous immunoglobulin infusion prevented relapses in patients with remission-exacerbation type chronic inflammatory demyelinating polyradiculoneuropathy]."
|3.||Adrenal Cortex Hormones (Corticosteroids)IBA
05/01/2009 - "Corticosteroids have been beneficial in controlled trials for CIDP. "
03/26/2002 - "Patients with apparent GBS who show persistent symptoms may benefit from corticosteroids or other treatment that is beneficial in the management of CIDP."
01/01/2002 - "To evaluate the efficacy of corticosteroids for treating chronic inflammatory demyelinating polyradiculoneuropathy. "
01/01/2001 - "To evaluate the efficacy of corticosteroids for treating chronic inflammatory demyelinating polyradiculoneuropathy. "
01/01/2002 - "A single randomised controlled trial with 35 participants provided weak evidence to support the conclusion from non-randomised studies that oral corticosteroids reduce impairment in chronic inflammatory demyelinating polyradiculoneuropathy. "
|4.||Prednisone (Sone)FDA LinkGeneric
03/01/2000 - "The occurrence of the oedema in a person with CIDP and FSGN and its improvement with prednisone, together with improvement in CIDP and FSGN, suggests that it was immune mediated, possibly due to increased capillary permeability. "
04/01/2010 - "Since the first clinical trial of prednisone in CIDP, several randomized trials have given rise to evidence-based therapeutic approaches. "
01/01/1978 - "Suggestive preliminary evidence from controlled 3-month clinical trials that prednisone improves chronic inflammatory polyradiculoneuropathy."
07/01/2009 - "The curative effect of GTC combined with prednisone in treating CIDP was better than that of prednisone alone."
05/01/2009 - "CIDP responds to prednisone, but long-term treatment can result in significant adverse effects. "
|5.||rituximab (Mabthera)FDA Link
03/01/2011 - "13 Italian CIDP patients were treated with rituximab after the partial or complete lack of efficacy of conventional therapies. "
08/24/2004 - "Rituximab may represent a successful therapy in otherwise refractory CIDP."
03/01/2011 - "To analyse the efficacy of rituximab in a large CIDP cohort. "
03/01/2011 - "A retrospective, observational and multicentre study on the use of rituximab in CIDP. "
05/01/2012 - "We report the effectiveness of Rituximab in a refractory childhood-onset CIDP and we suggest this treatment as an effective choice in unresponsive childhood CIDP."
06/01/2005 - "The frequency of such antibodies was significantly greater in both CIDP (p = 0.04) and GBS (p = 0.003) patients than in normal control subjects. "
09/01/1995 - "It was concluded that these antibodies may help to distinguish CIDP from other neuropathies and that they are diagnostically useful. "
09/01/1993 - "Further studies are needed to clarify fully the relationship between CIDP and MMN and the role of glycolipid antibodies in MMN and other motor syndromes."
08/01/1992 - "Further studies are clearly needed to clarify fully the relationship between CIDP and MMN and the relationship of MMN and other motor syndromes to various ganglioside antibodies."
10/01/2015 - "Four additional CIDP patients with anti-NF155 antibodies referred from other clinics were enrolled for clinical characterization. "
05/01/2013 - "A randomized double-blind trial was undertaken in 117 CIDP patients who received IGIV-C or placebo every 3 weeks for up to 24 weeks. "
02/01/2008 - "This study, the largest reported trial of any CIDP treatment, shows the short-term and long-term efficacy and safety of IGIV-C and supports use of IGIV-C as a therapy for CIDP."
11/01/2010 - "In addition to being statistically significant, all MCID analyses showed that CIDP improvements with IGIV-C are clinically meaningful. "
11/01/2010 - "IGIV-C or placebo was administered every 3 weeks for up to 24 weeks to 117 CIDP patients. "
06/01/2009 - "The results persuaded the US FDA and Health Canada to approve Gamunex for use in CIDP."
|8.||Cyclosporine (Ciclosporin)FDA LinkGeneric
03/01/2006 - "The author reports the long-term therapeutic efficacy of ciclosporin for patients with CIDP who did not show sustained improvement under steroid therapy. "
11/01/2005 - "This study demonstrates the efficacy of cyclosporine included in a regimen for the treatment of steroid-resistant chronic inflammatory demyelinating polyradiculoneuropathy in two children. "
12/01/2013 - "For refractory CIDP, a retrospective study showed the possibility of functional improvement in 24% of cases after adjunction of an immunomodulatory agent; cyclosporine was associated with the highest rate of adverse events or side effects. "
01/01/2012 - "[Successful cyclosporine treatment in 2 patients with refractory CIDP, involving monitoring of both AUC(0-4h) and trough levels]."
11/01/2005 - "We conclude that cyclosporine is an effective drug in the treatment of children with steroid-resistant chronic inflammatory demyelinating polyradiculoneuropathy."
09/01/2010 - "Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study."
04/14/2009 - "Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: the ICE Study."
07/01/2008 - "The results of this ICE trial demonstrated the efficacy of IVIg in CIDP, with a significantly higher response rate versus placebo after 24 weeks of treatment (P = 0.0002). "
07/01/2008 - "The ICE (IGIV CIDP Efficacy trial) study group undertook the largest ever trial of IVIg for CIDP, which demonstrated for the first time the long-term efficacy of IVIg. "
05/01/2013 - "Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG--the ICE study."
|10.||Cyclophosphamide (Cytoxan)FDA LinkGeneric
06/25/2002 - "High-dose cyclophosphamide can be given safely to patients with CIDP and patients with disease persistence after standard therapy may have a response that lasts for over 3 years and results in long-term disease remission."
10/01/2007 - "Three MS and five CIDP patients received cyclophosphamide (200 mg/kg) for refractory disease. "
10/01/2007 - "High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients."
03/01/2005 - "High-dose cyclophosphamide can markedly improve functionality and quality of life for patients with severe refractory CIDP."
06/25/2002 - "High-dose cyclophosphamide without stem-cell rescue for refractory CIDP."
01/01/2015 - "Moderate- to high-quality evidence from two small trials shows that plasma exchange provides significant short-term improvement in disability, clinical impairment, and motor nerve conduction velocity in CIDP but rapid deterioration may occur afterwards. "
01/01/2012 - "Moderate to high quality evidence from two small trials showed that plasma exchange provides significant short-term improvement in disability, clinical impairment and motor nerve conduction velocity in CIDP but rapid deterioration may occur afterwards. "
01/01/1982 - "It is too early to draw any conclusion from these studies other than that the double-blind study employed here is feasible and should provide information on the efficacy of plasma exchange in CIDP if its effect is prompt and large. "
01/01/2012 - "To evaluate the efficacy of plasma exchange in CIDP. "
01/01/2004 - "To evaluate the efficacy of plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. "
03/01/1998 - "We were not able to determine whether immunoadsorption plasmapheresis or double-filtration plasmapheresis was more effective for the patients with CIDP. "
03/01/1998 - "The present study strongly suggests that plasmapheresis with concomitant steroid therapy is very useful for both short- and long-term treatment of CIDP patients."
08/01/1998 - "We conclude that DFPP was useful for the subgroups of CIDP patients, but the underlying immuno-pathological background that determine the efficacy of plasmapheresis should be elucidated."
07/01/2007 - "This review evaluates the role of plasmapheresis in CIDP."
07/01/2007 - "Plasmapheresis for chronic inflammatory demyelinating polyradiculoneuropathy."
01/01/2009 - "Patients with diabetes with CIDP significantly improved after immunotherapy and during follow-up. "
02/01/2014 - "Recently, it was reported that diabetic radiculoplexus neuropathies as well as CIDP respond favorably to immunotherapy. "
04/15/2007 - "The results of the present study suggest that subclinical CNS involvement in CIDP is not uncommon in Japanese patients and that CIDP with subclinical CNS involvement is more demyelinative thus responsive to immunotherapies while those without have more axonal damage and less responsive to immunotherapies."
01/01/2006 - "Neurophysiologically probable CIDP patients should be given a trial of immunotherapy."
10/01/2015 - "The difference in immunotherapy response supports a fundamental difference between CIDP (immune attack on Schwann cells and myelin) and MMN (attack on nodes of Ranvier and axons)."
09/01/2005 - "We here initially retrospectively analyzed the motor nerve conduction study results of 20 consecutive patients with a clinical diagnosis of CIDP (four performed prior to, and 16 after, treatment initiation) to assess the sensitivity of six published sets of criteria (Nicolas et al., 2002; Thaisetthawatkul et al., 2002; Ad Hoc Subcommittee of the American Academy of Neurology AIDS Taskforce, 1991; Magda et al., 2003; Hughes et al., 2001; Saperstein et al., 2001), as well as four combinations (Nicolas et al., 2002; Ad Hoc Subcommittee of the American Academy of Neurology AIDS Taskforce, 1991; Hughes et al., 2001; Saperstein et al., 2001, each individually combined with Thaisetthawatkul et al., 2002). "
06/01/2003 - "This review offers an approach to the evaluation and management of patients with CIDP and highlights the difficult clinical problems in those who do not respond or frequently relapse after treatment with standard therapies such as patients with CIDP and concomitant axonal loss, and the assessment of those with CIDP and concurrent diseases such as diabetes mellitus."
10/01/2015 - "Follow-up nerve conduction studies in CIDP after treatment with IGIV-C: Comparison of patients with and without subsequent relapse."
01/01/2009 - "We report on a patient with CIDP who has been in remission for more than 3 years after treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP on two occasions."
07/01/2008 - "To report a case of a patient with tremor associated with chronic inflammatory demyelinating neuropathy (CIDP) that improved after treatment with pregabalin. "
|5.||Stem Cell Transplantation
06/01/2014 - "Autologous haematopoietic stem cell transplantation (AHSCT) has been performed as a last treatment resort in a few therapy-refractory cases with CIDP. "
06/01/2014 - "Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP."
12/01/2008 - "Chronic inflammatory demyelinating polyradiculoneuropathy: a role for haematopoietic stem cell transplantation?"
01/01/2009 - "Successful repeated treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP."
05/01/2008 - "Successful repeated treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP."